2017 Medical Devices Fund winners announced


Monday, 11 September, 2017

The NSW Government announced the winners of the Medical Devices Fund at a ceremony held last month at Parliament House. The program invests in the development and commercialisation of medical devices and related technologies in NSW, with over $6.61 million split between this year’s four lucky winners.

“The NSW Government is taking home-grown medical innovation to the next level, firmly placing this state at the forefront of global health technology,” said NSW Health Minister Brad Hazzard, who announced the winners.

“This fund gives entrepreneurs the opportunity to get game-changing ideas to market, not only keeping medical device companies in NSW, but significantly improving health outcomes and even saving patients’ lives.”

This year’s Medical Device Fund winners are:

  • SpeeDx (awarded $2.5 million), for the commercialisation of the first single test worldwide that detects sexually transmitted infections and antibiotic resistance.
  • MedLogical Innovations (awarded $1.25 million), whose ProFocal-Rx drug allows more than 30% of prostate cancer patients to have minimally invasive therapy and preserve their prostate gland.
  • Baymatob (awarded $1.47 million), whose non-invasive patch Oli is a capable of monitoring pregnancy and labour remotely, allowing for real-time observation.
  • Western Sydney Local Health District (awarded $1.39 million), whose Mu Catheter reduces hypertension by de-nerving the renal artery using a transcatheter microwave.

Since it began in 2013, the NSW Medical Devices Fund has awarded more than $41 million for 24 different technologies. For more information on the fund, visit www.health.nsw.gov.au/ohmr/mdf.

Related News

A pre-emptive approach to treating leukaemia relapse

The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...

Long COVID abnormalities appear to resolve over time

Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...

RNA-targeted therapy shows promise for childhood dementia

Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd